Clinical Trials Logo
  1. Home
  2. Brain Tumor, Primary
  3. NCT05775458

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology

Brain Tumor, Primary Clinical Trial

Official title:
Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme

Clinical Trial Summary

Gliomas are the most frequent type of primary brain tumors in adults; among them glioblastoma multiforme (GBM) is the most malignant, being associated with the worst prognosis. Glutamate (Glu) is an aminoacid, responsible for essential functions in the Central Nervous System (CNS), acting both as metabolite and neurotransmitter. It is essential for regulating cellular metabolism and developmental synaptogenesis, cellular migration, differentiation and death. Recent scientific evidences have demonstrated alteration in Glu synthesis and signaling being directly involved in GBM growth and invasion

Clinical Trial Description

Glu and its scavenger's levels are measurable both in serum and in the cerebral-spinal fluid (CSF), thus making them ideal markers for tumor aggressiveness and disease activity as well as a potential target for new therapeutic approaches. Serum and CSF levels of glutamic oxaloacetic transaminase (GOT1), Glutamate Pyruvate Transaminase (GPT) and glutamate and aspartate levels of a total of 40 patients will be collected. Molecular biology analyses will be conducted and oncological and imaging data will be collected during follow-up in patients enrolled in the present studies. MRI imaging as well as blood sampling will be performed at definite timepoints (baseline and 3, 6 and 9 months follow-up). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05775458
Study type Observational
Source IRCCS San Raffaele
Contact Sincinelli Laura
Phone 0226436658
Email sincinelli.laura@hsr.it
Status Recruiting
Phase
Start date June 1, 2020
Completion date September 30, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06057168 - Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas Phase 3
Recruiting NCT04427384 - Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Completed NCT03323450 - Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory N/A
Completed NCT00241670 - Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Phase 3
Not yet recruiting NCT01445691 - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Recruiting NCT06282562 - FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients N/A
Recruiting NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent Phase 2
Completed NCT00001574 - A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Completed NCT04365647 - Intra-operative Variation in Size of Brain Tumors After Craniotomy
Not yet recruiting NCT06185686 - Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
Withdrawn NCT04776980 - Multimodality MRI and Liquid Biopsy in GBM Early Phase 1
Completed NCT03262636 - Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow) Phase 1
Active, not recruiting NCT02006407 - A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors N/A
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Terminated NCT04901806 - Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors Phase 1
Recruiting NCT03373487 - Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery N/A
Not yet recruiting NCT06106997 - Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow N/A
Recruiting NCT05254197 - SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
Recruiting NCT05092802 - The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment Phase 2